Medisix Therapeutics
MediSix Therapeutics develops proprietary T-cell therapies, utilizing their unique Protein Expression BLocker (PEBL) technology to enhance T-cell function for patients with T-cell malignancies. The company addresses the limitations of existing CAR T-cell therapies, aiming to improve treatment outcomes for complex and rare cancers and autoimmune diseases.
- Biotechnology
Funding
Raised to date
$62.9MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 3 rounds
OUT$22.5M · Series B
Announced Apr 2021
Disclosed cumulative: $62.9M
Founders
Founder details are not available yet.
Product
Problem
Existing CAR T-cell therapies face challenges in treating T-cell malignancies due to the difficulty of targeting malignant T-cells without also harming healthy T-cells. This limitation hinders the effectiveness of CAR T-cell therapy for complex and rare cancers and autoimmune diseases.
Solution
MediSix Therapeutics is developing T-cell therapies using its proprietary Protein Expression BLocker (PEBL) technology to enhance T-cell function and overcome the challenges of treating T-cell malignancies. The PEBL technology allows for more precise targeting of malignant T-cells, improving treatment outcomes for patients with complex and rare cancers and autoimmune diseases. By leveraging this technology, MediSix aims to expand the applicability and efficacy of T-cell therapies.
Target Audience
The primary target audience includes patients with complex and rare T-cell malignancies and autoimmune diseases, as well as the healthcare providers who treat them.
Features
- Proprietary Protein Expression BLocker (PEBL) technology for precise targeting of malignant T-cells.
- Focus on improving and expanding T-cell function.
- Robust pipeline of research in T-cell therapies.
- Development of therapies for complex and rare T-cell malignancies and autoimmune diseases.